{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:18:45Z","timestamp":1764260325315},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Retinopathy of prematurity (ROP) is a major cause of visual impairment in premature infants, often requiring surgical interventions in advanced stages. This retrospective case series study investigates non-surgical management for Stage 4A ROP, specifically the use of combined laser therapy and intravitreal anti-vascular endothelial growth factor (VEGF) injections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ten eyes from five infants with Stage 4A ROP were treated with a combined laser and anti-VEGF approach. Comprehensive follow-up examinations were conducted to evaluate the treatment outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study demonstrated successful retinal attachment without complications, showcasing the efficacy and safety of this non-surgical method. A comparison with surgical interventions highlighted the potential benefits in terms of reduced adverse effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This combined treatment emerges as a promising first-choice option for Stage 4A ROP, offering rapid regression without surgical intervention, particularly in early stages. However, larger randomized clinical trials are necessary to validate these findings and establish definitive guidelines for managing this complex condition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Combined laser and anti-VEGF therapy proved to be an effective and safe non-surgical approach for Stage 4A ROP, with the potential to reduce the need for surgery, especially in its early presentation. Further research is required to confirm these findings and provide comprehensive recommendations for clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-024-03434-5","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T09:02:17Z","timestamp":1713517337000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-surgical treatment of stage 4A retinopathy of prematurity"],"prefix":"10.1186","volume":"24","author":[{"given":"Ehsan","family":"Namvar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Attar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"issue":"6","key":"3434_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.semperi.2019.05.001","volume":"43","author":"BA Darlow","year":"2019","unstructured":"Darlow BA, Gilbert C. Retinopathy of prematurity \u2013 a world update. Semin Perinatol. 2019;43(6):315\u20136.","journal-title":"Semin Perinatol"},{"issue":"9902","key":"3434_CR2","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445\u201357. PubMed PMID: 23782686. Pubmed Central PMCID: PMC4389630. Epub 20130617. eng.","journal-title":"Lancet"},{"issue":"10","key":"3434_CR3","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Chan RP, Berrocal A, et al. International classification of retinopathy of prematurity. Ophthalmology. 2021;128(10):e51\u201368.","journal-title":"Ophthalmology"},{"key":"3434_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ajo.2020.05.025","volume":"218","author":"ME Hartnett","year":"2020","unstructured":"Hartnett ME. Retinopathy of prematurity: evolving treatment with Anti-Vascular endothelial growth factor. Am J Ophthalmol. 2020;218:208\u201313.","journal-title":"Am J Ophthalmol"},{"key":"3434_CR5","doi-asserted-by":"publisher","first-page":"884608","DOI":"10.3389\/fmed.2022.884608","volume":"9","author":"NO Taher","year":"2022","unstructured":"Taher NO, Ghaddaf AA, Al-Ghamdi SA, Homsi JJ, Al-Harbi BJ, Alomari LK, et al. Intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity: a systematic review and meta-analysis. Front Med. 2022;9:884608.","journal-title":"Front Med"},{"issue":"5","key":"3434_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10103-020-03130-y","volume":"36","author":"SH Narnaware","year":"2021","unstructured":"Narnaware SH, Bawankule PK. Role of LASERS in stage 4A retinopathy of prematurity (ROP). Lasers Med Sci. 2021;36(5):989\u201393.","journal-title":"Lasers Med Sci"},{"issue":"3","key":"3434_CR7","first-page":"365","volume":"101","author":"B Mueller","year":"2017","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2017;101(3):365\u201370. PubMed PMID: 27301450. Epub 20160614. eng.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3434_CR8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008\u201315. PubMed PMID: 25687024. Pubmed Central PMCID: PMC4414677. Epub 20150214. eng.","journal-title":"Ophthalmology"},{"issue":"2","key":"3434_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00417-016-3443-6","volume":"255","author":"EA Sukgen","year":"2017","unstructured":"Sukgen EA, Ko\u00e7luk Y. Treatment for stage 4A retinopathy of prematurity: laser and\/or ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2017;255(2):263\u20139. PubMed PMID: 27495302. Epub 20160806. eng.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"3434_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000\u20136. PubMed PMID: 22491394. eng.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"3434_CR11","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1097\/IAE.0b013e318159ec49","volume":"28","author":"A Kychenthal","year":"2008","unstructured":"Kychenthal A, Dorta P. 25-gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Retina. 2008;28(3):S65\u20138.","journal-title":"Retina"},{"issue":"8","key":"3434_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/IAE.0b013e3182551c54","volume":"32","author":"C Iwahashi-Shima","year":"2012","unstructured":"Iwahashi-Shima C, Miki A, Hamasaki T, Otori Y, Matsushita K, Kiuchi Y, et al. Intraocular pressure elevation is a delayed-onset complication after successful vitrectomy for stages 4 and 5 retinopathy of prematurity. Retina. 2012;32(8):1636\u201342.","journal-title":"Retina"},{"issue":"4","key":"3434_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/IAE.0b013e3181610f97","volume":"28","author":"EN El Rayes","year":"2008","unstructured":"El Rayes EN, Vinekar A, Capone A Jr. Three-year anatomic and visual outcomes after vitrectomy for stage 4B retinopathy of prematurity. Retina. 2008;28(4):568\u201372.","journal-title":"Retina"},{"issue":"10","key":"3434_CR14","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0161-6420(98)91023-5","volume":"105","author":"BJ Hinz","year":"1998","unstructured":"Hinz BJ, de Juan JE, Repka MX. Scleral buckling surgery for active stage 4A retinopathy of prematurity. Ophthalmology. 1998;105(10):1827\u201330.","journal-title":"Ophthalmology"},{"issue":"11","key":"3434_CR15","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/archopht.116.11.1446","volume":"116","author":"DR Chow","year":"1998","unstructured":"Chow DR, Ferrone PJ, Trese MT. Refractive changes associated with scleral buckling and division in retinopathy of prematurity. Arch Ophthalmol. 1998;116(11):1446\u20138.","journal-title":"Arch Ophthalmol"},{"key":"3434_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10103-011-1021-z","volume":"28","author":"SK Houston","year":"2013","unstructured":"Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG. Laser treatment for retinopathy of prematurity. Lasers Med Sci. 2013;28:683\u201392.","journal-title":"Lasers Med Sci"},{"issue":"4","key":"3434_CR17","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1111\/aos.12055","volume":"91","author":"Y Xu","year":"2013","unstructured":"Xu Y, Zhang Q, Kang X, Zhu Y, Li J, Chen Y, et al. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection. Acta Ophthalmol. 2013;91(4):e304-10. PubMed PMID: 23647944. Epub 20130507. eng.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"3434_CR18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","volume":"246","author":"S Honda","year":"2008","unstructured":"Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246(7):1061\u20133. PubMed PMID: 18320201. Epub 20080305. eng.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"3434_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/eye.2009.156","volume":"24","author":"LC Zepeda-Romero","year":"2010","unstructured":"Zepeda-Romero LC, Liera-Garcia JA, Guti\u00e9rrez-Padilla JA, Valtierra-Santiago CI, Avila-G\u00f3mez CD. Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond). 2010;24(5):931\u20133. PubMed PMID: 19557020. Epub 20090626. eng.","journal-title":"Eye (Lond)"},{"issue":"2","key":"3434_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213\u20136. PubMed PMID: 17965108. Epub 20071026. eng.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"3434_CR21","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1167\/iovs.08-1928","volume":"49","author":"YM Paulus","year":"2008","unstructured":"Paulus YM, Jain A, Gariano RF, Stanzel BV, Marmor M, Blumenkranz MS, et al. Healing of retinal photocoagulation lesions. Invest Ophthalmol Vis Sci. 2008;49(12):5540\u20135. PubMed PMID: 18757510. Epub 20080829. eng.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"3434_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-022-02689-0","volume":"22","author":"E Namvar","year":"2022","unstructured":"Namvar E, Bolkheir A, Emadi Z, Johari M, Nowroozzadeh MH. Outcomes of near confluent laser versus combined less dense laser and bevacizumab treatment of prethreshold ROP Type 1 Zone 2: a randomized controlled trial. BMC Ophthalmol. 2022;22(1):1\u20136.","journal-title":"BMC Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03434-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T09:02:36Z","timestamp":1713517356000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03434-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3434"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03434-5","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board of the Shiraz University of Medical Sciences approved the study and the tenets of the declaration of Helsinki and its later amendments were followed. All participants signed the informed consent form. This study has been approved by the ethics committee at Shiraz university of Medical Sciences (IR.SUMS.MED.REC.1402.326).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}